BLAU3 Share Price Performance
R$10.43
0.74 (7.61%)
5.2% undervalued intrinsic discount
R$11.00
Fair Value
Price R$10.43
AnalystLowTarget R$11.00
AnalystConsensusTarget R$12.83
AnalystHighTarget R$17.47
Fair ValueR$11.00
Share Pricen/a
Blau Farmacêutica S.A. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 6 Fair Values set on narratives written by author
BLAU3 Community Narratives
AN
Fair Value R$11 5.2% undervalued intrinsic discount
Latin American Pricing Pressures And Biosimilar Competition Will Cut Profits
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value R$12.83 18.7% undervalued intrinsic discount
Future Production Expansions Will Support Latin American Healthcare Demand
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
Fair Value R$17.47 40.3% undervalued intrinsic discount
Aging Latin American Populations Will Amplify Biotech And Biosimilar Demand
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Future Production Expansions Will Support Latin American Healthcare Demand
Key Takeaways Scaling production capacity and expanding into Latin America enhance growth potential, operating efficiency, and revenue diversification amid rising healthcare demand. Focus on biosimilars, specialty drugs, and disciplined investment strengthens margins and positions Blau for long-term success in emerging pharmaceutical markets.Read more
20
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
R$12.83
18.7% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
12.8% p.a.
Profit Margin
17.55%
Future PE
11.09x
Price in 2029
R$21.4
Aging Latin American Populations Will Amplify Biotech And Biosimilar Demand
Key Takeaways Blau's expansion, investments in innovation, and dominant position in biotech put it in a strong position for outsized growth and improved margins versus competitors. Its diversified portfolio, scalable production, and strong financials enable resilience, recurring growth, and flexibility for opportunistic M&A and capital returns.Read more
9
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
R$17.47
40.3% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
21.29% p.a.
Profit Margin
15.19%
Future PE
14.02x
Price in 2029
R$29.09
Latin American Pricing Pressures And Biosimilar Competition Will Cut Profits
Key Takeaways Heavy reliance on Latin American government contracts and regional concentration exposes Blau to political, economic, and regulatory instability, risking volatile earnings and unpredictable revenue streams. Limited global presence and lagging R&D capacity hinder Blau's competitiveness amid rising biosimilar competition and higher compliance costs, threatening sustained growth and profitability.Read more
27
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
R$11
5.2% undervalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
10.6% p.a.
Profit Margin
19.95%
Future PE
8.93x
Price in 2029
R$18.45
Trending Discussion
Recently Updated Narratives
AN
BLAU3: Upcoming US Expansion Move Will Support Bullish Margin Outlook
Fair Value: R$12.83 18.7% undervalued intrinsic discount
2 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
BLAU3: Upcoming US Subsidiary Investment Will Support A More Optimistic Outlook
Fair Value: R$17.47 40.3% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
BLAU3: Planned Stock Split And Payout Will Shape Balanced Return Outlook
Fair Value: R$11 5.2% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Blau Farmacêutica S.A. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
Mar 18, 2026
- 1.41
- 40.23%
- 18.35%
- 21.7%
About BLAU3
- Founded
- 1987
- Employees
- n/a
- CEO
- WebsiteView website
Blau Farmacêutica S.A., a pharmaceutical company provides drug products in Brazil, Argentina, Chile, Colombia, Uruguay, Ecuador, Peru, and the United States. Its products cover various areas, such as immunology, hematology, oncology, nephrology, infectology, and anesthesiology. The company offers uterine stimulator, antirheumatic, anaesthetics, antibiotics, feminine health care, biopharmaceuticals, oncologicals, hospital products, antivirals and antiretrovirals, biológicos, acid pump inhibitor, hemoderivatives, antithrombotic, and thrombolytics products. Blau Farmacêutica S.A. was incorporated in 1987 and is headquartered in Cotia, Brazil.
